Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.



Ecumicin is a compound that has garnered attention in scientific research for its potential medicinal properties. It is a macrocyclic tridecapeptide isolated from the bacterium Nonomuraea sp., which is a type of actinomycete. These microorganisms are known for their ability to produce a wide range of bioactive secondary metabolites, many of which have been explored for their pharmaceutical potential.

The interest in ecumicin primarily stems from its potent activity against Mycobacterium tuberculosis, the bacterium responsible for tuberculosis (TB). TB remains a major global health challenge, particularly because of the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of the pathogen, which complicate treatment efforts. Ecumicin has been found to exhibit strong inhibitory activity against these difficult-to-treat strains of M. tuberculosis by targeting a specific component of the bacteria's cell machinery, which is different from the targets of current TB drugs. This mechanism of action suggests that ecumicin could be a valuable lead compound for developing new anti-TB therapies, especially for cases where existing medications are no longer effective.

For information can be found in the references available within this website.